Skip to main content

Retail Clinics

  • La Roche-Posay launches new acne treatment

    NEW YORK — In an effort to help those suffering from acne, La Roche-Posay has introduced its new Effaclar K Daily Renovating Anti-Relapse Acne Treatment 1, a daily treatment to address the ongoing, recurring life cycle of acne.

    For the first time in a La Roche-Posay product, retinyl linoleate (a vitamin A derivative), salicylic acid and La Roche-Posay's exclusive lipo-hydroxy acid (LHA) molecule are combined to help treat mild acne and prevent its reoccurrence in acne sufferers of all ages.

  • MedCoach app aids patients with medication management

    SAN DIEGO — Tracking medication adherence and connecting to pharmacies when it's time to refill prescriptions are among the capabilities of a new iPhone and iPad application made by GreatCall.

    GreatCall announced the launch of MedCoach, a medication management app that the company said would help customers better manage their overall well-being for free.

  • Smarticle Industries brings StingOut to market

    HONOLULU — Smarticle Industries on Wednesday announced the launch of StingOut, a product designed to soothe the sting of the box jellyfish and the Portuguese man-of-war, which has been found in waters from Texas and Florida to the northeastern United States.

  • Rash of Tylenol recalls not over

    FORT WASHINGTON, Pa. — McNeil Consumer Healthcare on Tuesday initiated another recall at the retail level of one product lot (60,912 bottles) of Tylenol extra strength caplets in 225-count bottles because of a small number of odor reports, including a musty, moldy odor.

    The uncharacteristic musty, moldy odor has been linked to the presence of trace amounts of a chemical known as 2,4,6-tribromoanisole (TBA).

    The product lot number (ABA619) for the recalled product can be found on the side of the bottle label. The recalled product was manufactured in February 2009.

  • Study: Tradjenta reduces blood sugar, weight among patients

    SAN DIEGO — New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.

    Boehringer Ingelheim and Eli Lilly presented data from the study of Tradjenta (linagliptin) at the American Diabetes Association’s 71st Scientific Sessions in San Diego last weekend. The study showed reductions in blood sugar and weight, and a low incidence of abnormally low blood sugar, known as hypoglycemia.

    The FDA approved Tradjenta as a treatment for Type 2 diabetes in May.

  • New campaign seeks to teach consumers about foodborne illnesses

    WASHINGTON — A new multimedia public service campaign that is designed to help families prevent food poisoning in the home has made its debut.

  • Lansinoh debuts new Italian Momma brand

    BOSTON — Drug Store News editor-in-chief Rob Eder interviewed Lansinoh Labs VP sales Michelle McLaughlin here at NACDS Marketplace about the company’s leading position in the natural feeding category, and an exciting new line of products from Europe, which Lansinoh acquired this year and currently is launching to U.S. retailers.

  • Xlear unveils nasal spray products for adults, kids

    OREM, Utah — Xlear recently announced the release of two new products: Xlear nasal spray and Kids Xlear nasal spray.

    The new Xlear nasal sprays are formulated with xylitol, a 5-carbon sugar alcohol found in many fruits and vegetables. The Kids Xlear nasal spray retails for approximately $6.99. The adult version of Xlear nasal spray retails for $6.99 and also is available in an easy-to-inhale “Pump-Mist” dispenser, retailing for $13.49.

X
This ad will auto-close in 10 seconds